Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
B. Riley Securities analyst Yuan Zhi initiated coverage on Radiopharm Theranostics Limited RADX with a Buy rating and ...
Fintel on MSN9h
BMO Capital Initiates Coverage of Avidity Biosciences (RNA) with Outperform Recommendation
Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Outperform ...
Avidity Biosciences initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Avidity Biosciences (RNA) with an Outperform rating and $72 price target Avidity’s pipeline includes ...
Avidity Biosciences price target lowered to $48 from $51 at BofA
BofA lowered the firm’s price target on Avidity Biosciences (RNA) to $48 from $51 and keeps a Buy rating on the shares. The firm rolled the ...
Avidity Biosciences (NASDAQ:RNA) Earns Sector Outperform Rating from Analysts at Scotiabank
Scotiabank began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report issued on Friday morning, ...